Search results for "EPATITI"

showing 10 items of 1589 documents

Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy

2020

Chronic hepatitis B virus (HBV) infection may be reactivated by immunosuppressive drugs in patients with autoimmune inflammatory rheumatic diseases. This study evaluates HBV serum markers&rsquo

0301 basic medicineMicrobiology (medical)HBsAgmedicine.medical_specialtyimmunosuppressive therapyHbv markersmedicine.disease_causeMicrobiologyGastroenterologyArticleVirus03 medical and health sciences0302 clinical medicineVirologyInternal medicinemedicineIn patientlcsh:QH301-705.5Hepatitis B virusbusiness.industryrheumatic patientsvirus diseasesHBV vaccineHBV markersmedicine.diseaseConnective tissue diseasedigestive system diseasesVaccinationTiter030104 developmental biologylcsh:Biology (General)030211 gastroenterology & hepatologybusinessHBV markers; HBV vaccine; immunosuppressive therapy; rheumatic patientsMicroorganisms
researchProduct

Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers …

2018

To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with…

0301 basic medicineMicrobiology (medical)MalePediatricsmedicine.medical_specialty030106 microbiologyImmunization SecondaryBooster doseAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccines03 medical and health sciences0302 clinical medicineImmunogenicity VaccineSuspensionsGermanyTetanus ToxoidMedicineHumansHepatitis B Vaccines030212 general & internal medicineVaccines CombinedDiphtheria-Tetanus-acellular Pertussis VaccinesImmunization ScheduleCzech RepublicHaemophilus VaccinesBooster (rocketry)business.industryDiphtheriaImmunogenicityVaccinationInfant NewbornInfantmedicine.diseaseRotavirus vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesPneumococcal vaccinePediatrics Perinatology and Child HealthFemalebusinessThe Pediatric infectious disease journal
researchProduct

Highly heterogeneous mutation rates in the hepatitis C virus genome.

2016

Spontaneous mutations are the ultimate source of genetic variation and have a prominent role in evolution. RNA viruses such as hepatitis C virus (HCV) have extremely high mutation rates, but these rates have been inferred from a minute fraction of genome sites, limiting our view of how RNA viruses create diversity. Here, by applying high-fidelity ultradeep sequencing to a modified replicon system, we scored >15,000 spontaneous mutations, encompassing more than 90% of the HCV genome. This revealed >1,000-fold differences in mutability across genome sites, with extreme variations even between adjacent nucleotides. We identify base composition, the presence of high- and low-mutation clusters a…

0301 basic medicineMicrobiology (medical)Mutation rateGenotypeHepatitis C virusImmunologyGenome ViralHepacivirusBiologymedicine.disease_causeVirus ReplicationApplied Microbiology and BiotechnologyMicrobiologyGenome03 medical and health sciencesMutation RateMolecular evolutionGenetic variationGeneticsmedicineHumansTransversionGenetics030102 biochemistry & molecular biologyNucleotidesGenetic VariationHigh-Throughput Nucleotide SequencingCell BiologyResistance mutationHepatitis C030104 developmental biologyViral replicationRNA ViralRepliconNature microbiology
researchProduct

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

2021

Introduction: In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization's elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for HCV, approved for 8-week treatment in patients without cirrhosis, and with compensated cirrhosis (CC). Previously, 12 weeks of therapy was recommended for patients with CC. Shortened treatment may reduce the burden on healthcare resources, allowing more patients to be treated. This study presents the benefits that 8-week vs 12-week treatment with G/P may have in Italy. Methods: A multicohort Marko…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationTreatment duration030106 microbiologyPopulationTreatment duration03 medical and health sciences0302 clinical medicineHealth careTreatment duration.Medicine030212 general & internal medicineeducationOriginal ResearchHepatitis C viruseducation.field_of_studyGlecaprevir/pibrentasvirbusiness.industryGlecaprevirPibrentasvirInfectious DiseasesItalyEmergency medicineObservational studyGlecaprevir / pibrentasvirHepatitis C virubusinessInfectious Diseases and Therapy
researchProduct

Assessment of ISO Method 15216 to Quantify Hepatitis E Virus in Bottled Water

2020

Hepatitis E virus (HEV) is one of the causative agents of water-borne human viral hepatitis and considered in Europe an emerging zoonotic pathogen. Analysis of bottled water through a standard method validated for HEV can contribute towards the risk management of this hazard. Putting some recent reports by the European Food Safety Authority in place, this study aimed to assess the performance of the concentration and extraction procedures described in ISO 15216-1:2017 for norovirus and hepatitis A virus on HEV detection. Following the ISO recommendation, the bottled water samples were spiked using serially diluted HEV fecal suspensions together with mengovirus as process control and concent…

0301 basic medicineMicrobiology (medical)viruses010501 environmental sciencesmedicine.disease_cause01 natural sciencesMicrobiologyArticleVirus03 medical and health sciencesConcentration methodsHepatitis E virusconcentration methodVirologymedicinelcsh:QH301-705.50105 earth and related environmental sciencesDetection limitChromatographyBottled waterChemistryExtraction (chemistry)RT-qPCRBottled watermedicine.diseaseTiter030104 developmental biologylcsh:Biology (General)NorovirusViral hepatitisHepatitis E Virus (HEV)
researchProduct

Viability RT-qPCR to Distinguish Between HEV and HAV With Intact and Altered Capsids

2018

The hepatitis E virus (HEV) is an emerging pathogen showing a considerable increase in the number of reported cases in Europe mainly related to the ingestion of contaminated food. As with other relevant viral foodborne pathogens, real-time reverse transcriptase polymerase chain reaction (RT-qPCR) is the gold standard for HEV detection in clinical, food, and environmental samples, but these procedures cannot discriminate between inactivated and potentially infectious viruses. Thus, the aim of this study was to develop a viability PCR method to discriminate between native, heat-, and high-pressure processing (HPP)-treated HEV using the hepatitis A virus (HAV) as a cultivable surrogate. To thi…

0301 basic medicineMicrobiology (medical)viruses030106 microbiologylcsh:QR1-502viability RT-qPCRBiologymedicine.disease_causeMicrobiologylcsh:Microbiologylaw.invention03 medical and health sciencesHepatitis E viruslawmedicineIngestionPolymerase chain reactionOriginal ResearchInfectivitybusiness.industryfoodborne virusGold standard (test)Food safetyVirologyReverse transcriptaseHAVfood safety030104 developmental biologyCapsidHEVbusinessintercalating dyeFrontiers in Microbiology
researchProduct

Effect of (−)-epigallocatechin gallate at different pH conditions on enteric viruses.

2017

Epigallocatechin gallate (EGCG), a flavonoid from green tea, is said to have extensive antimicrobial activity in a wide range of food spoilage or pathogenic fungi, yeast and bacteria. In this work, the antiviral activity of EGCG was assessed against hepatitis A virus (HAV) and murine norovirus (MNV), a human norovirus surrogate, at different temperatures, contact times and pH conditions by cell-culture methods. EGCG was effective in reducing the titers of HAV and MNV in a dose-dependent manner at neutral pH and 25 and 37 °C, while no effect was reported at 4 °C. HAV and MNV infectivity was completely removed after overnight treatment with EGCG at 2.5 mg/mL at 37 °C. Furthermore, results als…

0301 basic medicineNatural antimicrobialsviruses030106 microbiologyFlavonoidved/biology.organism_classification_rank.speciesBiologyEpigallocatechin gallatecomplex mixturesMicrobiologyCatechins03 medical and health scienceschemistry.chemical_compoundheterocyclic compoundsInfectivitychemistry.chemical_classificationved/biologyfood and beveragesCatechinbiology.organism_classificationAntimicrobialYeastchemistryMurine norovirusHepatitis A virusBacteriaFood ScienceMurine norovirus
researchProduct

Difference in Markers of Microbial Translocation and Cell Apoptosis in HIV Monoinfected and HIV/HCV Coinfected Patients

2019

Abstract Immune activation in human immunodeficiency virus (HIV) infection is driven by microbial translocation and in HIV patients is one of the contributors to faster progression of liver disease along with increased cell apoptosis. The aim of the study was to compare microbial translocation and apoptosis markers in HIV monoinfected and HIV/hepatitis C virus (HCV) coinfected patients, depending on HIV immune status and antiretroviral treatment (ART). We analysed data for 78 HIV monoinfected and 105 HIV/HCV coinfected patients from the Rīga East University Hospital. Lipopolysaccharide (LPS), endotoxin core antibodies (EndoCAb), cytokeratin 18 (CK18) and cyto-chrome c (Cyt-c) levels were me…

0301 basic medicineNecrosismicrobial translocationScience030106 microbiologyChromosomal translocation03 medical and health sciences0302 clinical medicinePharmacotherapyImmune systemmedicine030212 general & internal medicineMultidisciplinarybiologybusiness.industrylipopolysaccharideQapoptosisvirus diseasesHepatitis Cmedicine.diseaseVirologyApoptosisbiology.proteinmedicine.symptomAntibodybusinessMicrobial translocationProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association f…

2018

Abstract Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict …

0301 basic medicineNephrologyDirect-acting antiviral agentmedicine.medical_treatment030232 urology & nephrologyDiseaseHepacivirusurologic and male genital diseasesSeverity of Illness IndexLiver disease0302 clinical medicineRisk FactorsChronic kidney diseasePrevalenceRenal Insufficiency030212 general & internal medicineChronicCooperative BehaviorChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Antiviral Agents; Cooperative Behavior; Expert Testimony; Hepacivirus; Hepatitis C; Humans; Infectious Disease Medicine; Internal Medicine; Italy; Kidney Transplantation; Nephrology; Renal Insufficiency Chronic; Risk Factors; Severity of Illness Index; Societies; Disease ManagementSocieties MedicalKidney transplantationInfectious Disease Medicineeducation.field_of_studyEvidence-Based MedicineGastroenterologyDisease ManagementHepatitis CGeneral MedicineHepatitis CHCV in renal transplantationHCV infectionInfectious DiseasesTreatment OutcomeChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Hepatology; GastroenterologyItalyNephrologyEmergency Medicine030211 gastroenterology & hepatologyHemodialysisHumanMicrobiology (medical)medicine.medical_specialtyConsensus030106 microbiologyPopulationConsensuAntiviral AgentsRisk Assessment03 medical and health sciencesRenal DialysisInternal medicineChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infectionInternal MedicinemedicineHumansRenal Insufficiency ChroniceducationExpert TestimonyAntiviral AgentHepaciviruHepatologybusiness.industryRisk FactorHepatitis C Chronicmedicine.diseaseKidney TransplantationTransplantationDirect-acting antiviral agentsSocietiesbusinessChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Hepacivirus; Hepatitis C; Humans; Italy; Renal Insufficiency ChronicChronic kidney disease Direct-acting antiviral agents HCV in renal transplantation HCV infection NephrologyKidney disease
researchProduct

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

2019

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both existing controversies and newly emerging perspectives, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop.

0301 basic medicineOccult HBV infectionHepatitis B virusmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaHbv reactivationMEDLINEHBV reactivationOBImedicine.disease_cause03 medical and health sciences0302 clinical medicineHBV S variantRisk FactorsmedicineHumansHepatitis B AntibodiesIntensive care medicineComputingMilieux_MISCELLANEOUSHepatitis B virusHepatitis B Surface AntigensHepatologyHBV cccDNALiver Neoplasmsvirus diseasesHBV cccDNA; HBV reactivation; HBV S variants; HBV transmission; Hepatocellular carcinoma; OBI; Occult HBV infectionHBV S variantsHepatitis Bmedicine.diseaseOccultdigestive system diseases3. Good healthHBV S variants; HBV cccDNA; HBV reactivation; HBV transmission; Hepatocellular carcinoma; OBI; Occult HBV infection030104 developmental biologyLiverHepatocellular carcinomaDNA Viral030211 gastroenterology & hepatologyHBV transmission[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct